Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer
- PMID: 21792076
- PMCID: PMC3158278
- DOI: 10.1097/JTO.0b013e318223bf05
Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer
Abstract
Introduction: Studies from selected candidate genes suggest that single-nucleotide polymorphisms (SNPs) involved in glutathione metabolism, DNA repair, or inflammatory responses may affect overall survival (OS) in stages I to II or low-stage non-small cell lung cancer (LS-NSCLC); however, results are inconclusive. In this study, we took a systematic pathway-based approach to simultaneously evaluate the impact of genetic variation from these three pathways on OS after LS-NSCLC diagnosis.
Methods: DNA from 647 patients with LS-NSCLC was genotyped for 480 SNPs (tag-SNPs) tagging 57 genes from the three candidate pathways. Associations of tag-SNPs with OS were assessed at the individual SNP and whole gene levels, adjusting for age, tumor stage, surgery type, and adjuvant therapy. The genotype combinations of the SNPs associated with OS were also estimated.
Results: Among the 412 tag-SNPs that were successfully genotyped and passed quality assessments, 28 showed association with OS (p < 0.05). Two of the 28 were estimated to have less than a 20% chance of being false positives (rs3768490 in GSTM5: p = 1.32 × 10, q = 0.06; rs1729786 in ABCC4: p = 9.25 × 10, q = 0.20). Gene-based analysis suggested that in addition to GSTM5 and ABCC4, variation in two other genes, PTGS2 and GSTA2, was also associated with OS.
Conclusions: We describe further evidence that variations in genes involved in the glutathione and inflammatory response pathways are associated with OS in patients with LS-NSCLC. Further studies are warranted to verify our findings and elucidate their functional mechanisms and clinical utility leading to improved survival for patients with lung cancer.
Figures


Similar articles
-
Association between genetic variants in pre-microRNAs and survival of early-stage NSCLC.J Thorac Oncol. 2013 Jun;8(6):703-10. doi: 10.1097/JTO.0b013e318288dc0a. J Thorac Oncol. 2013. PMID: 23470291
-
Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients.Ann Oncol. 2010 Oct;21(10):2011-2016. doi: 10.1093/annonc/mdq212. Epub 2010 May 3. Ann Oncol. 2010. PMID: 20439344 Free PMC article.
-
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.Clin Lung Cancer. 2013 Jul;14(4):433-9. doi: 10.1016/j.cllc.2013.01.004. Epub 2013 Mar 22. Clin Lung Cancer. 2013. PMID: 23522953
-
The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.Med Oncol. 2014 May;31(5):959. doi: 10.1007/s12032-014-0959-7. Epub 2014 Apr 11. Med Oncol. 2014. PMID: 24722796
-
DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.Clin Lung Cancer. 2009 Mar;10(2):118-23. doi: 10.3816/CLC.2009.n.015. Clin Lung Cancer. 2009. PMID: 19362955
Cited by
-
Aerobic Exercise Improves Radiation Therapy Efficacy in Non-Small Cell Lung Cancer: Preclinical Study Using a Xenograft Mouse Model.Int J Mol Sci. 2024 Feb 27;25(5):2757. doi: 10.3390/ijms25052757. Int J Mol Sci. 2024. PMID: 38474004 Free PMC article.
-
Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.Tumour Biol. 2015 Jul;36(7):5451-7. doi: 10.1007/s13277-015-3211-y. Epub 2015 Feb 13. Tumour Biol. 2015. PMID: 25677905
-
A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection.PLoS One. 2015 Oct 13;10(10):e0140216. doi: 10.1371/journal.pone.0140216. eCollection 2015. PLoS One. 2015. PMID: 26462029 Free PMC article.
-
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.Lung Cancer (Auckl). 2011 Dec 29;3:1-14. doi: 10.2147/LCTT.S13256. eCollection 2012. Lung Cancer (Auckl). 2011. PMID: 28210120 Free PMC article. Review.
-
Genetic variations and patient-reported quality of life among patients with lung cancer.J Clin Oncol. 2012 May 10;30(14):1699-704. doi: 10.1200/JCO.2010.34.5629. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454423 Free PMC article.
References
-
- International Agency for Research on Cancer GLOBALCAN 2008. Int J Cancer. 2010;127:2893–2917. - PubMed
-
- Hoffman PC, Mauer AM, Vokes EE. Lung Cancer. Lancet. 2000;355:479–485. - PubMed
-
- Yang P, Allen MS, Aubry MC, et al. Clinical Features of 5,628 Primary Lung Cancer Patients: Experience at Mayo Clinic from 1997-2003. Chest. 2005;128:452–462. - PubMed
-
- Yang P, Ebbert JO, Sun Z, et al. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol. 2006;24:1761–1769. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials